Diagnosis and management of COPD in Māori and Pacific peoples
The health burden of Chronic Obstructive Pulmonary Disease (COPD) for Māori and Pacific peoples represents one of the most significant healthcare disparities in New Zealand. To reduce this gap it is recommended that practices adopt a tailored approach towards COPD management in Māori and Pacific peoples that focuses on community awareness, early diagnosis, smoking cessation and education for patients and their families.

The burden of COPD

Chronic Obstructive Pulmonary Disease (COPD) is estimated to affect 15% of all New Zealanders aged over 45 years. It is the fourth leading cause of death in New Zealand behind cancer, heart disease and stroke. COPD is permanent, disabling and frequently progressive. Over 85% of cases of COPD are caused by inhalation of tobacco smoke.

COPD in Māori and Pacific peoples

Amongst New Zealanders aged 50 – 64 years, Māori are approximately five times more likely to die from COPD-related causes than non-Māori and are affected by COPD up to 20 years earlier. COPD is ranked as the third highest health priority for Pacific peoples in the Auckland DHB region.

There is also evidence that COPD may be under-diagnosed in New Zealand, especially among Māori. In a study of 3500 randomly selected people aged over 25 years in the greater Wellington area, 736 people were referred for pulmonary testing. Overall, 16% of those tested had COPD, and 23% of Māori in the group had COPD.

Hospital discharge rates (Figure 1) show that Māori and Pacific peoples are three to four times more likely to be admitted to hospital for COPD than people in other ethnic groups in New Zealand.

Figure 1: Age-standardised hospital discharge rates in New Zealand with a primary diagnosis of COPD, per 1000 enrolled patients by ethnicity

Communicating risk

Understanding COPD is an important part of management. Visual aids, such as the airway diagrams in the Asthma Foundation’s “Breathe easier with COPD” booklet, are useful tools to demonstrate what COPD is and show its damaging effects on the lungs. Encouraging people to take educational material home is an effective way to involve families and increase understanding.

Another approach is to use examples that relate to everyday life. Focusing on the importance of kaumātua (elders) on the marae and within whānau may be a good way to emphasise the potential impact that COPD can have if kaumātua were absent.

When finishing a consultation, a good approach to see if the patient has understood a message is to ask; “When your whānau asks what advice I gave you, what will you say?”

The Asthma Foundation provides downloadable booklets on its website, including “Breathe easier with COPD”. Available from: http://www.asthmafoundation.org.nz/resources.php

Spirometry devices

Equipment of a high standard is required to take accurate spirometry measurements. Software should display a real-time flow volume graph adjusted for body temperature. Results should be able to be printed and the equipment easily dismantled for cleaning and disinfection. Flow-based spirometers need to be regularly checked with a calibrated syringe. Training in the use of a spirometry device is recommended.

The Asthma Foundation provides information on spirometry courses for health professionals. A list of recommended portable spirometers is available from: http://www.asthmafoundation.org.nz/spirometry.php

Promoting awareness may encourage Māori and Pacific peoples with COPD to contact their general practice earlier. Some patients may delay visiting their doctor due to the slowly progressive nature of the disease, while others may be dismissive of their symptoms, e.g. just a “smoker’s cough” or “just being older and unfit”. Financial barriers to accessing services are also likely to contribute.7

Every Māori or Pacific person who is a current, or ex-smoker, or has household members that smoke should be made aware of the:

- Support that is available to help them stop smoking
- Symptoms of COPD and the need to visit a health professional if a family member displays symptoms
- High impact COPD has on Māori and Pacific communities

Once a person has symptoms of COPD, lung damage has already occurred. This damage cannot be reversed, but can be substantially slowed through smoking cessation and prevention of exacerbations.

“Support not blame” is an important approach for health professionals engaging with people who have COPD. A feeling of judgement or blame, because of the association between smoking and COPD, may cause people to present to their general practice later than they otherwise would have. General practice staff need to be seen as welcoming and supportive.

Testing for COPD

Spirometry

Spirometry is the recommended method for diagnosing COPD.4 Ideally this should be performed with a device that allows electronic analysis of results (see “Spirometry devices”). International guidelines recommend that spirometry should be offered to any person aged over 40 years with any of the following characteristics:2

- Chronic cough (may be sporadic and unproductive)
- Chronic sputum production (phlegm)
- Dyspnoea that is persistent or progressive and worse with exercise
- History of exposure to tobacco, occupational smoke, dust or chemicals
- Family history of COPD

Due to the earlier age of onset and increased burden of COPD in Māori and Pacific peoples, testing for COPD in selected people who are at increased risk should begin at a younger age.
Rates of smoking in Māori and Pacific peoples are unacceptable

In 2009, 21% of New Zealanders aged 15 – 64 years were current smokers. Smoking rates were higher for Māori (males 40.2%, females 49.3%) and Pacific peoples (males 32.3%, females 28.5%) in the same age group. This is the primary reason Māori and Pacific peoples are disproportionately affected by COPD. Encouragingly, survey results show that smoking rates among younger Māori and Pacific peoples may be decreasing. The 2011 ASH smoking survey found that Māori secondary school students had the greatest decline in daily smoking rates, with a change from 14.1% in 2010 to 10.3% in 2011. Rates among Pacific students reduced from 7.0% to 5.9%.

Aukati Kaipaipa is a face-to-face smoking cessation service that is accessible in most communities. The programme provides Māori access to NRT, motivational counselling and other activities. A list of providers is available on the Aukati Kaipaipa website: www.aukatikaipaipa.co.nz/contact-us

For further information see: “Smoking cessation for Māori”, BPJ 22 (Jul, 2009)

Training to provide smoking cessation support for Pacific peoples is provided by the Heart Foundation. This consists of one day of theory training and one day of follow-up support. For further information see: www.heartfoundation.org.nz/programmes-resources

A new approach to smoking cessation using a “buddy” system

People with COPD who continue to smoke often feel judged. This perception may prevent people attending consultations, accessing treatment or even leaving their home. A recent small trial in a deprived area of the United Kingdom has shown some success in overcoming this.

People with COPD who have successfully stopped smoking are assigned as “buddies” to other motivated people with COPD who are current smokers. The “buddies” are given brief training in smoking cessation and then provide support and encouragement for their “buddy” during the cessation attempt. Results from the programme in 2011 showed that of 30 people who had used this support service, the four-week abstinence rate was over 80% and abstinence at 12 months was 50%. This compares to abstinence rates of 44% and 23% respectively for other smokers using varenicline and psychosocial support to aid their cessation attempt.

This experience from the United Kingdom is an example of whānaungatanga (togetherness and support) being applied to smoking cessation and may be directly transferable to Māori and Pacific communities in New Zealand.
A diagnosis of COPD is defined as a post-bronchodilator forced expiratory volume (in one second) to forced vital capacity ratio (FEV1/FVC) of < 0.7.10

The peak expiratory flow rate (PEFR) should not be used in the diagnosis or management of COPD as it is a measure of airflow in large airways.

Assessing the severity of COPD
Assessment of COPD severity should take into account the following:2

- Level of breathlessness (Table 1)
- Spirometry results (Table 2)
- Exacerbation risk – calculated from the number of exacerbations experienced in the previous 12 months: less than two exacerbations is low risk, two or more is high risk
- Presence of co-morbidities – influences risk of hospitalisation and overall mortality risk

Management of COPD
Once a diagnosis of COPD has been made, there is strong evidence that smoking cessation reduces the rate of lung function decline.10 People with COPD who smoke, typically smoke more cigarettes per day than other smokers and have a comparatively higher physical dependence to nicotine.15

Motivating a person with COPD to stop smoking (i.e. using “ABC” – ask, brief advice, cessation support) should be the primary management focus, followed by pharmacological treatment, pulmonary rehabilitation and management of exacerbations.

For further information on smoking cessation see: “Update on smoking cessation”, BPJ 33 (Dec, 2010).
Pharmacological treatment of COPD

Medicines for COPD are used to improve patient comfort and exercise tolerance while reducing the frequency of exacerbations. No medicine currently available has been conclusively shown to modify the long-term decline in lung function associated with COPD. Medicine choice should be based upon severity of symptoms and patient-specific response (Table 3, over page). It is important that patients and their whānau monitor symptoms in order to discuss management with their healthcare team. If inhaled medicines are used, training in inhaler technique is essential and inhaler technique should be regularly assessed.

Choosing a treatment regimen

The following points are generally applicable when selecting medicines for the management of stable COPD:2

- Inhaled bronchodilators are preferable to oral bronchodilators
- When symptoms are mild, short-acting bronchodilators are preferable to long-acting formulations
- When symptoms are more severe, long-acting bronchodilators are superior due to increased duration of action and a reduction in the risk of exacerbations. There is no strong evidence to recommend one long-acting formulation over another and treatment choice should be based on patient perception of symptom relief
- When COPD is severe and the risk of exacerbations is high, the addition of inhaled corticosteroids is indicated
- Suggested starting doses of medicines are listed in Table 4 (over page)

Short-acting beta-2 agonists (SABA), e.g. salbutamol, terbutaline, are usually prescribed as “rescue” medicine (as required) for the relief of breathlessness.

Short-acting anticholinergics, e.g. ipratropium, have been shown to improve quality of life and decrease the need for oral corticosteroid treatment, while decreasing the risk of adverse effects compared to SABA.10

Short-acting combinations, e.g. salbutamol and ipratropium, have been shown to improve spirometry results and reduce the need for oral corticosteroids, compared to ipratropium alone.10

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description of breathlessness</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Only gets breathless after strenuous exercise</td>
</tr>
<tr>
<td>1</td>
<td>Gets short of breath when hurrying on the level or walking up a slight hill</td>
</tr>
<tr>
<td>2</td>
<td>Walks slower than people of the same age due to breathlessness, or has to stop for breath when walking at own pace on the level</td>
</tr>
<tr>
<td>3</td>
<td>Stops for breath after walking for 100 m or after a few minutes on the level</td>
</tr>
<tr>
<td>4</td>
<td>Too breathless to leave the house, or breathless when dressing</td>
</tr>
</tbody>
</table>

A symptom grade of 0 or 1 indicates few symptoms, a grade ≥ 2 indicates a high level of symptoms

Table 2: Classification of airflow limitation severity in patients with FEV1/FVC < 0.7.2

<table>
<thead>
<tr>
<th>Classification</th>
<th>Post-bronchodilator FEV1*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>≥ 80% Predicted</td>
</tr>
<tr>
<td>Moderate</td>
<td>≥ 50% to &lt; 80% Predicted</td>
</tr>
<tr>
<td>Severe</td>
<td>≥ 30% to &lt; 50% Predicted</td>
</tr>
<tr>
<td>Very severe</td>
<td>&lt; 30% Predicted</td>
</tr>
</tbody>
</table>

* Most spirometers provide predicted values from healthy population studies that account for height, age and gender
### Table 3: Recommended initial pharmacological treatment of COPD.

<table>
<thead>
<tr>
<th>Severity</th>
<th>First-line</th>
<th>Second-line</th>
</tr>
</thead>
<tbody>
<tr>
<td>Few symptoms and low risk of exacerbations</td>
<td>Short-acting anticholinergic or SABA</td>
<td>Combined short-acting bronchodilators or Long-acting bronchodilator</td>
</tr>
<tr>
<td>Many symptoms and low risk of exacerbations</td>
<td>Long-acting anticholinergic or LABA</td>
<td>Long-acting anticholinergic + LABA</td>
</tr>
<tr>
<td>Few symptoms and high risk of exacerbations</td>
<td>ICS + LABA or Long-acting anticholinergic</td>
<td>Long-acting anticholinergic + LABA</td>
</tr>
<tr>
<td>Many symptoms and high risk of exacerbations</td>
<td>ICS + LABA or Long-acting anticholinergic</td>
<td>ICS + LABA + long-acting anticholinergic</td>
</tr>
</tbody>
</table>

### Table 4: Suggested starting doses of inhaled medicines for COPD

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Dose per puff</th>
<th>Number of puffs</th>
<th>Frequency</th>
<th>Delivery device</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Beta-2 agonist</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salbutamol</td>
<td>100 micrograms</td>
<td>2</td>
<td>Four times daily as required</td>
<td>MDI</td>
</tr>
<tr>
<td>Terbutaline</td>
<td>250 micrograms</td>
<td>2</td>
<td>Four times daily as required</td>
<td>DPI</td>
</tr>
<tr>
<td>Salmeterol</td>
<td>25 micrograms</td>
<td>2</td>
<td>Twice daily</td>
<td>MDI</td>
</tr>
<tr>
<td></td>
<td>50 micrograms</td>
<td>1</td>
<td>Twice daily</td>
<td>DPI</td>
</tr>
<tr>
<td><strong>Anticholinergic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ipratropium</td>
<td>20 micrograms</td>
<td>2</td>
<td>Four times daily</td>
<td>MDI</td>
</tr>
<tr>
<td>Titropium</td>
<td>18 micrograms</td>
<td>1</td>
<td>Once daily</td>
<td>DPI</td>
</tr>
<tr>
<td><strong>Combination inhalers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salbutamol and ipratropium</td>
<td>100/20 micrograms</td>
<td>2</td>
<td>Four times daily</td>
<td>MDI</td>
</tr>
<tr>
<td>Budesonide and eformoterol</td>
<td>200/6 micrograms</td>
<td>2</td>
<td>Twice daily</td>
<td>DPI</td>
</tr>
<tr>
<td>Fluticasone and salmeterol</td>
<td>125/25 micrograms</td>
<td>2</td>
<td>Twice daily</td>
<td>MDI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(dose different for DPI)</td>
</tr>
<tr>
<td><strong>Corticosteroid</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budesonide</td>
<td>400 micrograms</td>
<td>1</td>
<td>Twice daily</td>
<td>DPI</td>
</tr>
<tr>
<td>Fluticasone</td>
<td>250 micrograms</td>
<td>2</td>
<td>Twice daily</td>
<td>MDI or DPI</td>
</tr>
</tbody>
</table>

MDI = metered dose inhaler, DPI = dry powder inhaler
Inhaled anticholinergics and cardiovascular risk

A 2008 meta analysis assessing 17 trials found that inhaled anticholinergics were associated with a significantly increased risk of cardiovascular death, myocardial infarction or stroke in people with COPD. However, a 2010 study of almost 20,000 people with COPD found that tiotropium was associated with a reduction in cardiovascular events and cardiovascular mortality. But another study, published in the same journal, showed an increased risk of cardiovascular events associated with the use of ipratropium in a large population with COPD. There is ongoing controversy regarding the interpretation of these results. There is currently no biological explanation why the two anticholinergics would have different cardiovascular effects and a dose-response relationship for the effect has not been demonstrated. Both medicines have low systemic absorption. Until the evidence is understood better, the potential adverse effects of ipratropium and tiotropium need to be balanced against the known benefits of these medicines.

Long-acting beta-2 agonists (LABA), e.g. salmeterol, reduce exacerbations and improve symptoms, and are more effective at maintaining symptom relief than SABAs. They are effective for at least 12 hours and can be administered twice daily.

Long-acting anticholinergics, e.g. tiotropium, reduce exacerbations and have an effect over 24 hours and are therefore administered once daily. There is an increased risk of dry mouth and urinary retention. Tiotropium is fully subsidised under Special Authority.

Inhaled corticosteroids (ICS), e.g. budesonide, fluticasone, decrease the exacerbation rate compared to placebo, and increase quality of life, but do not appear to prevent lung function deterioration and may increase the risk of pneumonia. Systemic absorption does occur and long-term use must be balanced against the risk of adverse effects. Beclomethasone is also available but there is less evidence for its use in COPD.

Combination inhaled corticosteroids with long-acting beta-2 agonists, e.g. budesonide with eformoterol and fluticasone with salmeterol (fully subsidised under Special Authority), can be taken twice daily.

Theophylline, available in long-acting tablets or oral liquid, is used as a third-line treatment for people with COPD when other bronchodilators are either ineffective or unavailable for long-term treatment.

Long-term continuous oxygen therapy (16 – 24 hours per day) may be of benefit in selected patients with COPD who have a PaO₂ consistently less than 55 mm Hg. Home oxygen is usually initiated by a respiratory physician. The patient must be clinically stable and have stopped smoking for at least one month.

Managing exacerbations

A COPD exacerbation is an acute event where symptoms deteriorate beyond normal day-to-day variation to the point where a change in the medicine regimen is required. This is characterised by an increase in dyspnoea, cough or sputum production, most commonly caused by a respiratory tract infection. COPD exacerbations are known to increase the rate of lung function decline and are associated with increased rates of mortality. The higher rate of hospitalisation amongst Māori and Pacific peoples due to COPD suggests that COPD exacerbations affect these groups more significantly than other groups. People with COPD need to be able to identify exacerbations and seek treatment early.
Strategies to reduce the risk of exacerbations include:
- Improving exercise capacity
- Influenza vaccination (annually – funded for people with COPD) and pneumococcal vaccination (five-yearly) for people with COPD and their families
- Reducing the risk of infection by avoiding people who have symptoms of an upper respiratory tract infection, e.g. cough, rhinitis, nasal congestion, sneezing
- Avoiding smoke and other environmental pollutants, e.g. smog
- Optimised control of co-morbidities
- Warm and well ventilated homes

Treatment options for exacerbations include bronchodilation with SABA, either alone or in combination with short-acting anticholinergics; doubling the dose or increasing the frequency of use, e.g. from four times to six times per day, if necessary. If the patient is using a long-acting bronchodilator then this should also be continued during the exacerbation. A short course of oral corticosteroids, e.g. 20 – 40 mg, once daily, for 7 – 14 days, may also reduce recovery time, improve lung function and reduce the risk of a relapse.10

Antibiotics should only be used to treat exacerbations when there is an increase in cough, dyspnoea, sputum volume or purulence. First-line treatment choice is amoxicillin 500 mg, three times a day, for five days. Second-line is doxycycline 100 mg, twice daily, for five days if the patient is penicillin allergic or has had a recent course of amoxicillin.

When a patient has a history of exacerbations, or may have difficulty accessing a general practice, a step-wise self-management plan, including optimising bronchodilator use, oral corticosteroids and indications for antibiotic use may be useful.10

Referral to secondary care should be considered when:
- A previously mobile patient can no longer walk short distances
- Dyspnoea prevents eating or sleeping
- There is an inability to manage at home due to exhaustion
- A high-risk co-morbidity is present, e.g. heart failure or ischaemic heart disease
- There are sign of hypercapnia (CO₂ retention) present, such as altered mental state
- There is an inadequate response to treatment or uncertain diagnosis

For further information see: “Management of acute exacerbations of COPD in Primary Care”, BPJ 23 (Sept, 2009)

Pulmonary rehabilitation may improve symptoms of COPD

Pulmonary rehabilitation refers to programmes which combine multiple approaches to attempt to break the cycle of COPD, where decreased physical activity due to dyspnoea leads to further loss of fitness and eventual immobility. There is strong evidence that rehabilitation programmes improve the symptoms of COPD and reduce hospitalisations. Pulmonary rehabilitation also reduces muscle wasting and weight loss, and programmes that include psychosocial support have been associated with significant reductions in anxiety and depression.20, 21 The minimum time-frame for a rehabilitation programme to be beneficial appears to be six weeks, and the longer the programme lasts, the greater its effectiveness.2 Family members play an important role in motivating a person with COPD to remain compliant with their rehabilitation programme.

Weight loss is common in people with COPD as the added effort to breathe can increase energy requirements by 15–20%.22 People with COPD who are underweight have increased mortality rates. Pulmocare is a high fat, low carbohydrate dietary supplement, designed to minimise CO₂ production. It is available under Special Authority for people with hypercapnia as a result of COPD.


Psychosocial support is particularly important for Māori and Pacific peoples with COPD. People with COPD have an increased risk of developing symptoms of anxiety and depression, both of which are linked to poor health outcomes. In addition, Māori and Pacific adults have a higher prevalence of mental health disorders in general than other ethnic groups. Cognitive behavioural approaches have been shown to significantly reduce depression and improve the health status of people with severe COPD. Strategies include relaxation, breathing techniques, positioning and chest clearing techniques and modification of negative thoughts.25

For further information on pulmonary rehabilitation programmes contact the respiratory department at your local DHB. The Asthma Foundation’s “Breathe easier with COPD” booklets provide a list of suggested exercises that can be performed at home and practical ways of dealing with the stress and limitations of COPD.
Māori and Pacific peoples are three to four times more likely than people of other ethnicities to be hospitalised due to COPD (Figure 1, page 15). Tiotropium is known to reduce COPD exacerbations and related hospitalisations. It is available in New Zealand under Special Authority for patients with moderate or severe COPD.

Tiotropium dispensing rates in New Zealand by ethnicity (Figure 2) show that:
- Māori have a higher rate of tiotropium dispensing than other ethnicities, but are prescribed only one-third to one-half more tiotropium despite hospitalisation rates being three to four times greater.

- Pacific peoples have the same rate of hospitalisations for COPD as Māori, yet are prescribed less tiotropium than Māori or European/Other people.

It is unknown if these disparities are due to tiotropium not being prescribed to these patient groups, or if the prescriptions are not being collected. In addition, there is no available data on medicine compliance for people with COPD in New Zealand.

**Figure 2:** Age-standardised rates of tiotropium dispensing (items dispensed) in New Zealand per 1000 enrolled patients by ethnicity, 2008 to 2010

* Discharges source: As per Figure 1 Population source: As per Figure 1
The Tu Kotahi Asthma Trust

Formed in the Hutt Valley in 1995, the Tu Kotahi Trust provides a Marae-based “by Māori, for Māori” support programme for people with COPD. The goal of the group is to promote COPD education and a sense of togetherness and support (whānaungatanga) throughout the whānau.

A research programme is currently underway to quantify the programme’s outcomes. Anecdotal evidence from participants indicates that the Trust is achieving success in providing timely access to health care for Māori affected by COPD. The use of Te Reo Māori and understanding of culture (tikanga) and hospitality (manaakitanga) have created a non-threatening and supportive environment for Māori. One participant described this by saying:

“...at the hospital they’re speaking a language I could never understand, but you come here and sit down and use language that I understand...that’s a big barrier that got broken down...just getting to know on my level, instead of me climbing up to theirs.”

The group encourages participation in a regular exercise programme. Medicine compliance and management of exacerbations have improved through the delivery of simple demonstrations and visual explanations. Members are also encouraged to consider issues such as housing and co-morbidities when supporting people with COPD.

Through encouraging early engagement with individuals and their whānau, the Trust has identified a number of people in their early 30s and 40s who are in the early phase of COPD. This is likely to provide significantly better outcomes for these people, while simultaneously achieving financial savings through early disease management.

Raising community awareness and providing community-based resources for the diagnosis and management are important strategies in combating COPD.

ACKNOWLEDGEMENT
Thank you to Dr Matire Harwood, Clinical Director, Te Hononga O Tamaki Me Hoturoa, Auckland, Dr Peter Martin, Medical Advisor, The Quit Group and Associate Professor Jim Reid, Dunedin School of Medicine, University of Otago for expert guidance in developing this article.

References
A bestpractice Decision Support Module

Childhood Asthma

The bestpractice Childhood Asthma module assists clinicians in providing the most appropriate course of action for a patient depending on their symptoms and history. Individualised advice about what treatment to consider and when referral is appropriate is offered, as well as a personalised asthma action plan for each patient.

Progression through an initial consultation for a patient presenting with symptoms/risk factors for asthma. The probability of asthma is determined from this information and then management recommendations are provided.

Control and treatment of previously diagnosed asthma using a stepwise approach. This section includes information about appropriate choice of devices, dose, possible non-pharmacological management and when to refer.

Use the module to create a personalised Action Plan which clearly illustrates to the patient and caregivers:

- What inhaler to take
- When to take it
- How much to take
- What to do in the event of an emergency
- What might trigger the patient’s asthma

This PHARMAC funded module is FREE to General Practice